Metabolic Dysregulation and Cancer Risk Program (MeDOC)
The overall purpose of the MeDOC consortium is to enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk in individuals and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and potential targets for preventive and therapeutic interventions.
- PRINCIPAL INVESTIGATOR(S)
- ADDITIONAL INVESTIGATOR(S)
-
Kim Robien
Matt Barberio
- RESEARCH STAFF
-
Caitlin Mogan, Nisha Grover
- MAJOR PUBLICATIONS
-
Coming Soon
Project Overview:
MeDOC is a trans-NCI research program with participation from 4 National Cancer Institute divisions, 5 research grants from different institutions, and a CoC. The goal is to advance the current understanding of cancer’s connection to obesity and metabolic dysregulation in order to improve screening and risk prediction.
Funding Agency or Sponsor: